Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Alejandro Recio Boiles
Assistant Professor, Medicine - (Clinical Scholar Track)
Medicine
Overview
Research
More
Collaboration
(19)
Ricklie Julian
Mutual work: 8 Grants
Collaboration Details
Jennifer Segar
Mutual work: 8 Grants
Collaboration Details
Jennifer Hatcher
Mutual work: 2 Grants
Collaboration Details
Denise Roe
Mutual work: 2 Publications﹒1 Grant
Collaboration Details
Ronald Heimark
Mutual work: 5 Publications
Collaboration Details
Page 1 of 4
Previous page
Next page
Grants
(25)
A Phase 1, Multi-center, Open Label First-in-Human Study with ABBV-CLS-579 Alone and in Combination in Subjects with Locally Advanced or Metastatic Tumors
Active
·
2023
·
$0 / $830.5K
·
External
Co-Investigator (COI)
oncology,
clinical trials,
cancer treatment,
drug development,
immunotherapy
A Phase 1, Open-Label, Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects with Advanced Solid Tumors and Subsequent Expansio
Active
·
2023
·
$3.7M / $735.4K
·
External
Principal Investigator (PI)
cancer,
pharmacokinetics,
clinical effects,
intravenous administration,
safety
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Canc
Active
·
2023
·
$454.6K
·
External
Principal Investigator (PI)
prostate cancer,
cancer treatment,
clinical trial,
metastatic cancer,
drug combination
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study of IO-202 in Combination with Pembrolizumab in Subjects with Advanced, Relapsed, or Refractory Solid Tumors
Active
·
2023
·
$0 / $391.4K
·
External
Co-Investigator (COI)
immunotherapy,
cancer,
clinical trial,
combination therapy,
solid tumors
Phase 1 Study of Intratumoral Administration of VAX014 in Subjects with Advanced Solid Tumors
Active
·
2023
·
$0 / $352.4K
·
External
Co-Investigator (COI)
cancer immunotherapy,
clinical trial,
tumor microenvironment,
intratumoral therapy,
solid tumors
Page 1 of 5
Previous page
Next page
Publications
(28)
Recent
Health Disparities in Presentation, Treatment, Genomic Testing, and Outcomes of Pancreatic Cancer in Hispanic and Non-Hispanic Patients
2023
Impact of Aspirin Use on Outcomes in Patients With Hepatocellular Cancer: A Nationwide Analysis.
2023
Gender, Racial and Ethnic Differences in Pathologic Response Following Neoadjuvant Chemotherapy for Bladder Cancer Patients
2023
cancer treatment,
racial disparities,
pathologic response,
neoadjuvant chemotherapy,
gender differences
Prostate Cancer Disparities in Metastatic and Treatment Status for Hispanic Americans Based on Country of Origin Compared to Non-Hispanic Whites Using the National Cancer Database
2023
prostate cancer,
health disparities,
hispanic americans,
metastatic cancer,
treatment disparities
Disparities in prostate cancer: An ethnicity comparative focus among Hispanic Americans versus non-Hispanic whites.
2022
prostate cancer,
ethnicity,
health disparities,
hispanic americans,
non-hispanic whites
Pharmacotherapeutic options for pancreatic ductal adenocarcinoma
2022
Network meta-analysis NMA) of second-line 2L) treatment options in metastatic renal cell carcinoma.
2022
TROPHY-U-01 Cohort 3: Sacituzumab govitecan SG) in combination with pembrolizumab Pembro) in patients pts) with metastatic urothelial cancer mUC) who progressed after platinum PLT)based regimens.
2022
Is first-line immune checkpoint inhibitors ICI) beneficial to platinum-eligible patients pts) with advanced urothelial carcinoma aUC) a meta-analysis.
2021
immunotherapy,
urothelial carcinoma,
meta-analysis,
platinum-eligible patients,
first-line treatment
Using Advanced Molecular Profiling to Identify the Origin of and Tailor Treatment for an Intracranial Mass of Unknown Primary
2021
molecular profiling,
intracranial mass,
treatment tailoring,
cancer origin identification,
precision medicine